Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Long-Term Immunogenicity of the Norovirus GI.1/GII.4 Bivalent Virus-like Particle (VLP) Vaccine (NoV Vaccine) in Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03039790
Recruitment Status : Completed
First Posted : February 1, 2017
Last Update Posted : December 13, 2021
Sponsor:
Information provided by (Responsible Party):
Takeda

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate descriptively the long-term immunogenicity of at least 1 NoV vaccine administration.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Norovirus Biological: NoV Vaccine Phase 2

Detailed Description:

The drug being tested in this study is called NoV vaccine. NoV vaccine is being tested for protection against acute gastroenteritis (AGE) due to norovirus.

The study will enroll maximum of 575 participants. Participants who previously received NoV vaccine in studies NOR-107, NOR-210 and NOR-204 will be enrolled. Participants from study NOR-107 will enter the study at the time of their 3rd year post-primary vaccination, and from studies NOR-210 and NOR-204, at their 2nd year post-primary vaccination. The duration of participation in the study will be different for each participant.

This multi-center trial will be conducted in Belgium and the United States. The overall time to participate in this study is maximum 5 years after primary NoV vaccination. Participants will have a maximum of 4 visits over 3 years.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 528 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase 2, Long-Term Immunogenicity Follow-up Trial of Adult and Elderly Subjects Who Have Previously Received an Intramuscular Injection of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine
Actual Study Start Date : February 21, 2017
Actual Primary Completion Date : July 22, 2021
Actual Study Completion Date : July 22, 2021

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: NoV Vaccine
Participants who previously received NoV vaccine adjuvanted with aluminum as aluminum hydroxide or with monophosphoryl lipid A (MPL), injection, intramuscularly as planned in studies NOR-107, NOR-210 and NOR-204 will be assessed over 5 years post-primary vaccination. Vaccine formulations according to the parent trials: NOR-107, 210 and 204.
 Biological: NoV Vaccine
No NoV vaccine injection administered.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Geometric Mean Blocking Titers 50 percent (%) (GMBT50) of Anti-norovirus GI.1 VLP Antibodies [ Time Frame: Up to 5 years post-primary vaccination ]
    GMBT50 of anti-norovirus GI. VLP antibody titers as measured by the histo-blood group antigen (HBGA) blocking assay.

  2. GMBT50 of Anti-norovirus GII.4 VLP Antibodies [ Time Frame: Up to 5 years post-primary vaccination ]
    GMBT50 of anti-norovirus GII.4 VLP antibody titers as measured by the HBGA blocking assay.


Secondary Outcome Measures :
  1. Geometric Mean Titers (GMT) of Anti-norovirus GI.1 VLP Antibodies [ Time Frame: Up to 5 years post-primary vaccination ]
    GMT of anti-norovirus GI.1 VLP antibody titers as measured by total immunoglobulin (pan-Ig) enzyme-linked immunoassay (ELISA).

  2. GMT of Anti-norovirus GII.4 VLP Antibodies [ Time Frame: Up to 5 years post-primary vaccination ]
    GMT of anti-norovirus GII.4 VLP antibody titers as measured by pan-Ig ELISA.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

1. Male and female participants who previously received at least 1 dose of NoV vaccine in trials NOR-107, NOR-210 and NOR-204, have baseline and post-vaccination data, and completed the primary vaccination trial protocol as initially described.

Exclusion Criteria:

  1. Participation in any clinical trial is allowed, on condition that no investigational product is administered within 30 days prior to blood sampling.
  2. In the opinion of the investigator, the participant is not medically eligible to provide blood specimens.
  3. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the participant's ability to participate in the trial.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03039790


Locations
Layout table for location information
United States, Alabama
Simon-Williamson Clinic/Synexus Clinical Research US, Inc
Birmingham, Alabama, United States, 35211
United States, Arizona
Synexus Clinical Research US, Inc./Fountain Hills Family Practice, P.C.
Fountain Hills, Arizona, United States, 85268
United States, Colorado
Synexus Clinical Research US, Inc/Southwest Family Medicine
Littleton, Colorado, United States, 80127
United States, Florida
Miami Research Associates
Miami, Florida, United States, 33143
United States, Kansas
Johnson County Clin-Trials
Lenexa, Kansas, United States, 66219
United States, Missouri
St. Louis University, School of Medicine
Saint Louis, Missouri, United States, 63106
United States, New York
Regional Clinical Research Inc.
Endwell, New York, United States, 13760
University of Rochester
Rochester, New York, United States, 14642
United States, Texas
Benchmark Research Austin
Austin, Texas, United States, 78705
Belgium
Universiteit Antwerpen
Antwerpen, Belgium, 2610
Universitair Ziekenhuis Gent
Gent, Belgium, 9000
Sponsors and Collaborators
Takeda
Investigators
Layout table for investigator information
Study Director: Medical Director Takeda
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Takeda
ClinicalTrials.gov Identifier: NCT03039790    
Other Study ID Numbers: NOR-213
2016-004288-37 ( EudraCT Number )
U1111-1189-7907 ( Registry Identifier: WHO )
First Posted: February 1, 2017    Key Record Dates
Last Update Posted: December 13, 2021
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Access Criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
URL: https://vivli.org/ourmember/takeda/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Takeda:
Drug Therapy